Data from a phase III study have linked the advanced prostate cancer drug abiraterone acetate (ZYTIGA) to delayed pain progression and functional decline in a certain subset of advanced prostate cancer patients.
FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI
Follow Urology Times' coverage of the full-day FDA advisory committee meeting regarding Iterum Therapeutics' new drug application for oral sulopenem for uncomplicated urinary tract infection.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Collaboration to advance market launch of ProVate device for pelvic organ prolapse
The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
Darolutamide associated with more favorable tolerability vs other ARIs in nmCRPC
“Our study reveals potential differences in tolerance and effectiveness of AR inhibitors in practice, which can help clinicians and patients with treatment decisions," says Daniel J. George, MD.
Survey reveals generational trends in men’s health habits
“We saw in the survey that men are concerned with how the health decisions they make now will affect them in the future,” says Petar Bajic, MD.